PMID: 6161308Jan 1, 1981Paper

Expression of cell-surface HLA-DR, HLA-ABC and glycophorin during erythroid differentiation

Nature
J RobinsonM Greaves

Abstract

The unexpected discovery that Ia-like (HLA-DR) antigens in humans were present on blast cells from acute myeloblastic leukaemia led to the finding that normal granulocytic progenitors, in contrast to their mature descendents, also expressed HLA-DR antigens. Thus, anti-Ia sera stain a proportion of myeloblasts in normal bone marrow, inhibit myeloid progenitor (CFU-GM) colony formation in the presence of complement and can be used to label and separate CFU-GM on a fluorescence-activated cell sorter (FACS). Winchester et al. subsequently reported that erythroid progenitors (BFU-E and CFU-E) were also inhibited or killed by anti-Ia (p28,37) and complement. These observations raised the possibility that HLA-DR (or presumptive I-region equivalent) products might have a regulatory role in early haematopoiesis. We have now analysed HLA-DR and HLA-ABC antigen expression on normal erythroid progenitors using monoclonal antibodies to non-polymorphic determinants and fluorescence-activated cell sorting. In parallel experiments, we tested a monoclonal antibody to glycophorin, a well defined erythroid-specific cell-surface membrane glycoprotein. We report that HLA-DR, HLA-ABC and glycophorin are all expressed at various stages during erythro...Continue Reading

References

Jan 1, 1977·Cold Spring Harbor Symposia on Quantitative Biology·C J BarnstableM J Crumpton
Sep 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·R J WinchesterH E Broxmeyer
Nov 1, 1977·British Journal of Haematology·G JanossyK Welsh
Jan 1, 1979·Immunological Reviews·F M BrodskyW F Bodmer
Aug 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·J P AllisonJ Silver
Feb 1, 1978·The Journal of Experimental Medicine·D G NathanD E Housman
Oct 27, 1978·Biochimica Et Biophysica Acta·M Greaves, G Janossy
Apr 1, 1979·European Journal of Immunology·G BrownD Y Mason
Dec 8, 1977·Nature·R S BaschM F Greaves
Aug 1, 1978·The Journal of Experimental Medicine·R J WinchesterH G Kunkel
Jan 1, 1976·Annual Review of Biochemistry·V T MarchesiM Tomita
Apr 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·S F SchlossmanJ L Strominger
Mar 15, 1969·Nature·R Harris, J D Zervas

❮ Previous
Next ❯

Citations

Jan 1, 1991·International Journal of Cell Cloning·G ZauliG P Bagnara
Jan 1, 1981·Leukemia Research·M F GreavesG Goldstein
Jan 1, 1981·International Journal of Immunopharmacology·M GreavesP Kung
Apr 21, 1999·Experimental Hematology·J L MillerG P Rodgers
Jan 25, 2003·Tissue Antigens·M T CoirasM Sánchez-Pérez
Jul 2, 1981·The New England Journal of Medicine·J H FitchenM J Cline
May 12, 1983·The New England Journal of Medicine·L J LevittP L Greenberg
Jun 26, 1999·The New England Journal of Medicine·D G Nathan, C A Sieff
Nov 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·N S Young, S P Hwang-Chen
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·C G GahmbergL C Andersson
Apr 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·F LatronR S Accolla
Jan 1, 1993·Journal of Hematotherapy·L W TerstappenS Töpker
Oct 1, 1996·Tissue Antigens·M T ScupoliR S Accolla
Jan 3, 2001·The Journal of Clinical Investigation·K C SonntagC LeGuern
Jun 13, 2001·Biochemical and Biophysical Research Communications·S AokiM Kobayashi
Jan 1, 1982·Immunogenetics·V van HeyningenC M Steel
Sep 1, 1994·Transplant Immunology·R Huss, H J Deeg
May 1, 1997·Leukemia & Lymphoma·K MuroiM R Loken

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.